Evaluation of Five Screening Tools in Detecting Physical Frailty in Cirrhosis and Their Prognostic Role
- PMID: 39274382
- PMCID: PMC11396431
- DOI: 10.3390/jcm13175169
Evaluation of Five Screening Tools in Detecting Physical Frailty in Cirrhosis and Their Prognostic Role
Abstract
Background: Physical frailty (PF) is a syndrome of decreased physical function and reserves, preventing patients from coping with stressful events. PF screening tools in patients with liver cirrhosis (LC) can help evaluate the risk of complications and death. The aim of this study was to assess the performance of five screening tools in detecting PF and their ability to predict 18-month mortality in LC. Methods: The Short Physical Performance Battery (SPPB), Fried frailty phenotype (FFP), Clinical Frailty Scale (CFS) and 6-Minute Walk Test (6MWT) were compared with the Liver Frailty Index (LFI) as the method of reference. Patients with an LFI ≥ 4.5, SPPB ≤ 8, FFP ≥ 3, CFS ≥ 6 points, and those walking <250 m, were considered frail. Results: A total of 109 consecutive patients with stable LC were included [63.3% male, median age 62 years, (IQR 52-70), MELD 9 (7-14.5), 46.8% with decompensated LC (DC)]. PF was present in 23.9%, 27.5%, 41.3%, 13.8%, and 28.4% as assessed by the LFI, SPPB, FFP, CFS, and 6MWT, respectively. Cohen's kappa measurement of agreement of four of the tools with LFI was 0.568, 0.334, 0.439, and 0.502, respectively (p < 0.001 for each). Kaplan-Meier survival curves at 18 months showed higher mortality in frail patients compared to non-frail patients by any method (log rank p < 0.05). In the multivariate models, PF defined by any method emerged as an independent prognostic factor of 18-month mortality after adjustment for age, gender, and MELD-score. Conclusions: Patients characterized as frail by five screening tools were not identical. However, PF defined by either method was proven to be an independent poor prognostic factor for long-term mortality after adjustment for covariates.
Keywords: 6-Minute Walk Test; Clinical Frailty Scale; Cohen’s kappa measurement of agreement; Fried frailty phenotype; Liver Frailty Index; Short Physical Performance Battery; physical frailty; prognosis.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
A Comparison of Different Frailty Scores and Impact of Frailty on Outcome in Patients With Cirrhosis.J Clin Exp Hepatol. 2022 Mar-Apr;12(2):398-408. doi: 10.1016/j.jceh.2021.07.003. Epub 2021 Jul 21. J Clin Exp Hepatol. 2022. PMID: 35535083 Free PMC article.
-
Applicability and prognostic value of frailty assessment tools among hospitalized patients with advanced chronic liver disease.Croat Med J. 2021 Feb 28;62(1):8-16. doi: 10.3325/cmj.2021.62.8. Croat Med J. 2021. PMID: 33660956 Free PMC article.
-
A Rapid Bedside Screen to Predict Unplanned Hospitalization and Death in Outpatients With Cirrhosis: A Prospective Evaluation of the Clinical Frailty Scale.Am J Gastroenterol. 2016 Dec;111(12):1759-1767. doi: 10.1038/ajg.2016.303. Epub 2016 Aug 2. Am J Gastroenterol. 2016. PMID: 27481305
-
Frailty and Mortality Risk in COPD: A Cohort Study Comparing the Fried Frailty Phenotype and Short Physical Performance Battery.Int J Chron Obstruct Pulmon Dis. 2023 Jan 20;18:57-67. doi: 10.2147/COPD.S375142. eCollection 2023. Int J Chron Obstruct Pulmon Dis. 2023. PMID: 36711228 Free PMC article.
-
Four different frailty models predict health outcomes in older patients with stable chronic obstructive pulmonary disease.BMC Geriatr. 2022 Jan 16;22(1):57. doi: 10.1186/s12877-022-02750-z. BMC Geriatr. 2022. PMID: 35034605 Free PMC article.
Cited by
-
Impact of age on frailty in liver cirrhosis: a prospective cohort study.Clin Exp Med. 2025 Jun 13;25(1):203. doi: 10.1007/s10238-025-01747-3. Clin Exp Med. 2025. PMID: 40514576 Free PMC article.
References
-
- Dent E., Morley J.E., Cruz-Jentoft A.J., Woodhouse L., Rodríguez-Mañas L., Fried L.P., Woo J., Aprahamian I., Sanford A., Lundy J., et al. Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management. J. Nutr. Health Aging. 2019;23:771–787. doi: 10.1007/s12603-019-1273-z. - DOI - PMC - PubMed
-
- Cruz-Jentoft A.J., Bahat G., Bauer J., Boirie Y., Bruyère O., Cederholm T., Cooper C., Landi F., Rolland Y., Sayer A.A., et al. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16–31. doi: 10.1093/ageing/afy169. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources